D. E. Shaw & Co., Inc. Editas Medicine, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $2.75 Million - $5.11 Million	-70,000 Reduced 87.5%	10,000 $411,000
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $1.25 Million - $2.27 Million	40,000 Added 100.0%	80,000 $4.53 Million
Q4 2018 Feb 14, 2019	BUY	$18.19 - $31.79 $727,600 - $1.27 Million	40,000 New	40,000 $910,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.